The Role of miRNA in Papillary Thyroid Cancer in the Context of miRNA Let-7 Family

Perdas, Ewelina; Stawski, Robert; Nowak, Dariusz; Zubrzycka, Maria

doi:10.3390/ijms17060909

Cited by 47 publications

(35 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because RAS activation is associated with oncogenesis, downregulation of let‐7 could be essential in tumorigenesis. Downregulation of several members of let‐7 family is reported in development of several cancers such as PTC . The let‐7a‐2 is a member of let‐7 family whose its exact biologic pathways are not understood, however, decreased expression of let‐7a‐2 is associated with poor prognosis in non–small cell lung cancer .…”

Section: Discussionmentioning

confidence: 99%

“…Downregulation of several members of let-7 family is reported in development of several cancers such as PTC. 29 The let-7a-2 is a member of let-7 family whose its exact biologic pathways are not understood, however, decreased expression of let-7a-2 is associated with poor prognosis in non-small cell lung cancer. 30 Recent studies have demonstrated that let-7 regulates some oncogenic pathways, therefore, let-7a-2 T A B L E 2 Allelic and genotypic frequency of let7a-2 rs1143770 and pri-mir-34b/c rs4938723 polymorphisms in PTC and control groups is commonly believed to play a tumor suppressor role similar to other members of let-7 family.…”

Section: Discussionmentioning

confidence: 99%

“…30 Recent studies have demonstrated that let-7 regulates some oncogenic pathways, therefore, let-7a-2 T A B L E 2 Allelic and genotypic frequency of let7a-2 rs1143770 and pri-mir-34b/c rs4938723 polymorphisms in PTC and control groups is commonly believed to play a tumor suppressor role similar to other members of let-7 family. 29 The gene encoding let-7a protein was located on chromosome11q24.1. The relation between let7a-2 polymorphisms and several cancers has been reported.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Genetic polymorphisms of miRNA let7a‐2 and pri‐mir‐34b/c are associated with an increased risk of papillary thyroid carcinoma and clinical/pathological features

Heidari

Mohammadpour‐Gharehbagh

Eskandari

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

microRNAs (miRNAs) as a group of short noncoding RNAs are crucial molecules in transcriptional and translational regulation of oncogenes and tumor suppressor genes. Evidence showed there was an association between the miRNA polymorphisms and various cancers, including papillary thyroid carcinoma (PTC). The present study aims to evaluate the possible effects of let7a‐2 rs1143770 and pri‐mir‐34b/c rs4938723 polymorphisms on PTC susceptibility. A total of 120 patients with PTC and 130 age, sex, and race matched controls were enrolled in the case‐control study. The polymerase chain reaction‐restriction fragment length polymorphism method was used for genotyping of let7a‐2 rs1143770 and pri‐mir‐34b/c rs4938723 polymorphisms. The let7a‐2 rs1143770 CT and TT genotypes were associated with a 1.9‐fold and 2.2‐fold higher risk of PTC, respectively (P = 0.027 and P = 0.041). Moreover, the let7a‐2 rs1143770 polymorphism was associated with increased PTC risk in both dominant (2‐fold, P = 0.015) and the allelic model (1.5‐fold, P = 0.03). The frequency of pri‐mir‐34b/c rs4938723TC genotype was significantly higher in patients with PTC and associated with a two‐fold higher risk of PTC (P = 0.013). In addition, this polymorphism was associated with a 1.8‐fold increased risk of PTC in dominant model (P = 0.021). The let7a‐2 rs1143770CT genotype was associated with a 3.5‐fold increased risk of N1 stage in PTC patients (P = 0.04), however, pri‐mir‐34b/c rs4938723TC genotype was associated with a 3.4‐fold and 5.1‐fold increased risk of III‐IV stage and vascular invasion in PTC group, respectively (P = 0.04 and P = 0.04). In conclusion, the present study shows that let7a‐2 rs1143770 and pri‐mir‐34b/c rs4938723 polymorphisms could be susceptible factors for PTC and some clinical features.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic polymorphisms of miRNA let7a‐2 and pri‐mir‐34b/c are associated with an increased risk of papillary thyroid carcinoma and clinical/pathological features

Heidari

Mohammadpour‐Gharehbagh

Eskandari

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…Expression of let-7a, let-7,c, let-7d, let-7f, and let-7g has not been described in plasma. For the examined miRNAs (let-7b, let-7e, and let-7i), overexpression in plasma was found [10].…”

Section: Introductionmentioning

confidence: 97%

Analysis of Let-7 Family miRNA in Plasma as Potential Predictive Biomarkers of Diagnosis for Papillary Thyroid Cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

The most common histological type of thyroid cancer is papillary thyroid carcinoma (PTC). Radical resection of the thyroid gland is currently the recommended method of treatment. Almost 75% of thyroidectomies performed just for diagnostic purposes are benign. Thus, the confirmation of innovative and more precise noninvasive biomarkers holds promise for the detection of PTC, which may decrease the number of unnecessary thyroid lobectomies. In this work, using the droplet digital PCR (ddPCR) method, we have analyzed the level of five miRNAs (let-7a, let-7c, let-7d, let-7f, and let-7i) in the plasma of patients with PTC and compared them with those of a healthy control group to investigate whether miRNAs also have value in the management of PTC. Levels of four miRNAs, namely let-7a, let-7c, let-7d, and let-7f, were significantly higher in PTC patients than healthy controls. Thus, the analysis of circulating let-7 can be a useful tool and support the currently used methods for PTC diagnosis. However, our observation requires further research on a larger patient group.

show abstract

“…A pajzsmirigy daganatos állapotaiban felfedezett keringő mikroRNS-ek [18,19]. Kaukázusi népes-ségben ugyanakkor a miR-190 felül-, illetve a miR-95 alulexpresszálódott egészséges emberekhez és jóindulatú elváltozásokhoz viszonyítva [20].…”

Section: Táblázatunclassified

Keringő mikroRNS-ek az endokrin daganatok diagnosztikájában

et al. 2017

View full text Add to dashboard Cite

A mikroRNS-ek (miRNS, miR) rövid -19-25 nukleotidból álló -érett formájukban egyszálú, nem kódoló RNSmolekulák, amelyek a génexpressziót főként poszttranszkripcionális szinten befolyásolják. A mikroRNS-ek szerepet játszanak élettani folyamatokban, például a sejtdifferenciálódás és -proliferáció szabályozásában, egyedfejlődésben, vérképzésben, sejthalálban, míg aberráns expressziójuk számos betegség, köztük autoimmun betegségek, gyulladá-sok, vascularis betegségek vagy daganatok kialakulása során megfigyelhető. A mikroRNS-ek szövetspecifikus módon fejeződnek ki. Szöveti megjelenésük mellett különböző testfolyadékokban is megtalálhatóak. Így például a vérben, az anyatejben, az ondóban, nyálban, vizeletben stb. A testfolyadékokban megjelenő mikroRNS-ek, így különösen a vér keringő mikroRNS-ei, a daganatok kórisméjében mint minimálisan invazív diagnosztikai eszközök jöhetnek szóba. Az endokrin daganatokra jellemző leírt keringő mikroRNS-kifejeződések száma eddig alacsony, főként a papillaris pajzsmirigy-carcinomára, mellékvesekéreg-carcinomára, petefészekrákra, illetve egyes neuroendokrin tumorokra szorítkozik. Tekintettel arra, hogy e daganatok egy részének szövettani diagnózisa, a malignitás megállapítása nehéz, a keringő mikroRNS-ek kutatásában jelentős távlatok rejlenek. Orv. Hetil., 2017, 158(13), 483-490.Kulcsszavak: mikroRNS, daganat-biomarker, pajzsmirigydaganat, mellékvesekéreg-carcinoma, petefészek-daganat Circulating microRNAs in the diagnostics of endocrine neoplasmsMicroRNAs (miRNA, miR) are short -19-25 nucleotide long -single stranded (in their mature form), non-coding RNA molecules that regulate gene expression mostly at the posttranscriptional level. microRNAs are involved in the regulation of various physiological processes such as cell differentiation and proliferation, development, haematopoesis, cell death, while their aberrant expression is observed in numerous diseases, like autoimmune disorders, inflammations, vascular diseases or tumorigenesis. microRNAs are expressed in a tissue specific fashion. Beyond their appearance in tissues, they can be found in body fluids as well. microRNAs are present in blood, mother milk, semen, saliva, urine, etc. MicroRNAs in body fluids, especially the blood-borne circulating microRNAs can be exploited as minimally invasive biomarkers of tumor diagnosis. The number of endocrine tumor-associated circulating microRNA alterations is relatively low, mostly described for papillary thyroid cancer, adrenocortical cancer, ovarian and neuroendocrine tumors. As the histological diagnosis including the establishment of malignancy of some of these neoplasms is difficult, studies on circulating microRNAs might have great perspectives.Keywords: microRNA, tumor biomarker, thyroid neoplasm, adrenocortical carcinoma, ovarian neoplasm Decmann, Á., Perge, P., Nagy, Z., Butz, H., Patócs, A., Igaz, P. [Circulating microRNAs in the diagnostics of endocrine neoplasms]. Orv. Hetil., 2017, 158(13), 483-490. (Beérkezett: 2017 elfogadva: 2017. február ÖSSZEFOGLALÓ KÖZLEMÉNYRövidí...

show abstract

The Role of miRNA in Papillary Thyroid Cancer in the Context of miRNA Let-7 Family

Cited by 47 publications

References 36 publications

Genetic polymorphisms of miRNA let7a‐2 and pri‐mir‐34b/c are associated with an increased risk of papillary thyroid carcinoma and clinical/pathological features

Genetic polymorphisms of miRNA let7a‐2 and pri‐mir‐34b/c are associated with an increased risk of papillary thyroid carcinoma and clinical/pathological features

Analysis of Let-7 Family miRNA in Plasma as Potential Predictive Biomarkers of Diagnosis for Papillary Thyroid Cancer

Keringő mikroRNS-ek az endokrin daganatok diagnosztikájában

Contact Info

Product

Resources

About